Orchestra BioMed Shares Owned By Institutions vs. Return On Asset

OBIO Stock   5.68  0.11  1.97%   
Based on the measurements of profitability obtained from Orchestra BioMed's financial statements, Orchestra BioMed Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Orchestra BioMed's ability to earn profits and add value for shareholders. At this time, Orchestra BioMed's Price To Sales Ratio is very stable compared to the past year. As of the 27th of November 2024, Days Sales Outstanding is likely to grow to 13.75, though Operating Cash Flow Sales Ratio is likely to grow to (15.88). At this time, Orchestra BioMed's Net Interest Income is very stable compared to the past year. As of the 27th of November 2024, Interest Income is likely to grow to about 4 M, while Accumulated Other Comprehensive Income is likely to drop (10.5 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.120.9326
Fairly Up
Slightly volatile
For Orchestra BioMed profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Orchestra BioMed to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Orchestra BioMed Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Orchestra BioMed's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Orchestra BioMed Holdings over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.60)
Revenue Per Share
0.073
Quarterly Revenue Growth
1.356
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Orchestra BioMed Holdings Return On Asset vs. Shares Owned By Institutions Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Orchestra BioMed's current stock value. Our valuation model uses many indicators to compare Orchestra BioMed value to that of its competitors to determine the firm's financial worth.
Orchestra BioMed Holdings is considered to be number one stock in shares owned by institutions category among its peers. It also is considered to be number one stock in return on asset category among its peers . As of the 27th of November 2024, Return On Assets is likely to drop to -0.54. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orchestra BioMed's earnings, one of the primary drivers of an investment's value.

Orchestra Return On Asset vs. Shares Owned By Institutions

Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Orchestra BioMed

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
54.97 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Orchestra BioMed

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.39
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Orchestra Return On Asset Comparison

Orchestra BioMed is currently under evaluation in return on asset category among its peers.

Orchestra BioMed Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Orchestra BioMed, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Orchestra BioMed will eventually generate negative long term returns. The profitability progress is the general direction of Orchestra BioMed's change in net profit over the period of time. It can combine multiple indicators of Orchestra BioMed, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-10 K-10.5 K
Net Interest Income3.8 MM
Interest Income3.8 MM
Operating Income-51.5 M-48.9 M
Net Loss-49.1 M-51.6 M
Income Before Tax-49.1 M-51.6 M
Total Other Income Expense Net2.4 M2.5 M
Net Loss-20.7 M-21.7 M
Net Loss-49.1 M-51.6 M
Income Tax Expense119.1 K113.2 K
Change To Netincome501.3 K476.2 K
Net Loss(1.48)(1.55)
Income Quality 0.94  1.07 

Orchestra Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Orchestra BioMed. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Orchestra BioMed position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Orchestra BioMed's important profitability drivers and their relationship over time.

Use Orchestra BioMed in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.

Orchestra BioMed Pair Trading

Orchestra BioMed Holdings Pair Trading Analysis

The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Orchestra BioMed position

In addition to having Orchestra BioMed in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Semiconductor Thematic Idea Now

Semiconductor
Semiconductor Theme
Companies involved in production of semiconductor and semiconductor materials. The Semiconductor theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Semiconductor Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Orchestra BioMed Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Orchestra BioMed's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Orchestra Biomed Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Orchestra Biomed Holdings Stock:
Check out Your Equity Center.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
To fully project Orchestra BioMed's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Orchestra BioMed Holdings at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Orchestra BioMed's income statement, its balance sheet, and the statement of cash flows.
Potential Orchestra BioMed investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Orchestra BioMed investors may work on each financial statement separately, they are all related. The changes in Orchestra BioMed's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Orchestra BioMed's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.